D.E. Shaw & Co
ANIK icon

D.E. Shaw & Co’s Anika Therapeutics ANIK Stock Holding History

D.E. Shaw & Co’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-24,900
Closed -$1.02M – 4159
2014
Q1 		$1.02M Sell
24,900
-51,800
-68% -$1.93M ﹤0.01% 3011
2013
Q4 		$2.93M Buy
76,700
+47,100
+159% +$1.45M ﹤0.01% 2151
2013
Q3 		$709K Buy
+29,600
New +$664K ﹤0.01% 3334

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

D.E. Shaw & Co's ANIK Position: Q2 2026 in Review

D.E. Shaw & Co increased its Anika Therapeutics (ANIK) stake by 6.6% in Q2 2026, buying an estimated $226K and bringing the position to 245,066 shares worth $3.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2688.

D.E. Shaw & Co first reported a position in ANIK in Q2 2013 and has held it in 47 quarters since. The position peaked at $22.4M in Q3 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • D.E. Shaw & Co held 245,066 shares of Anika Therapeutics worth $3.59M as of Q2 2026.
  • D.E. Shaw & Co bought 15,270 Anika Therapeutics shares in Q2 2026, an estimated $226K.
  • Anika Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2688 holding.
  • D.E. Shaw & Co first reported a position in Anika Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • D.E. Shaw & Co's Anika Therapeutics position peaked at $22.4M in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.